Citations

Showing 10 of 108135 citations.

Latissimus dorsi detrusor myoplasty for bladder acontractility: a systematic review
Forte, Antonio J. , Boczar, Daniel , Huayllani, María T. , Moran, Steven L. , Okanlami, Oluwaferanmi , Ninković, Milomir, Broer, P. Niclas, Huayllani, Maria Tereza, Moran, Steven, Forte, Antonio Jorge

Mayo Clinic

Archives of Plastic Surgery | September 16, 2021 | Volume: 48 | Issue: 05 | Pages: 528-533

10.5999/aps.2021.00402 | PMID 34583440 Get It

Bladder acontractility affects several thousand patients in the United States, but the available therapies are limited. Latissimus dorsi detrusor myoplasty (LDDM) is a therapeutic option that allows patients with bladder acontractility to void voluntarily. Our goal was to conduct a systematic review of the literature to determine whether LDDM is a better option than clean intermittent catheterization (CIC) (standard treatment) in patients with bladder acontractility. On January 17, 2020, we conducted a systematic review of the PubMed/MEDLINE, Cochrane Clinical Answers, Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov databases, without time frame limitations, to identify articles on the use of LDDM for bladder acontractility. Of 75 potential articles, 4 fulfilled the eligibility criteria. The use of LDDM to treat patients with bladder acontractility was reported in four case series by the same group in Europe. Fifty-eight patients were included, and no comparison groups were included. The most common cause of bladder acontractility was spinal cord injury (n=36). The mean (±standard deviation) operative time was 536 (±22) minutes, postoperative length of hospital stay ranged from 10 to 13 days, and follow-up ranged from 9 to 68 months. Most patients had complete response, were able to void voluntarily, and had post-void residual volume less than 100 mL. Although promising outcomes have been obtained, evidence is still weak regarding whether LDDM is better than CIC to avoid impairment of the urinary tract among patients with bladder acontractility. Further prospective studies with control groups are necessary.
Heartburn As a Marker of the Success of Acid Suppression Therapy in Chronic Cough.
Badri, Huda , Mangi, Muhammad Asif , Tangaroonsanti, Anupong, DeVault, Kenneth R. , Lee, A. S., Satia, Imran , Bansal, Vikas , Houghton, Lesley A. , Smith, John A.

Mayo Clinic

No container title available | September 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-886153/v1 Get It

Abstract Purpose: Gastro-oesophageal reflux disease (GORD) is commonly thought to play an important role in chronic cough and patients are often empirically treated with acid suppression therapy. We sought to investigate the response rate to acid suppression treatment in patients with and without heartburn attending two specialist cough clinics. Methods: A retrospective review of 558 consecutive patients referred to two specialist cough clinics was performed (UK and US). Patients who were treated with acid suppression were included and their documented response to treatment collected. Binary logistic regression was used to ascertain the value of reported heartburn in predicting the response of chronic cough to acid suppression therapy. Results: Of 558 consecutive referrals, 238 patients were excluded due to missing data or cough duration of <8weeks. The remaining 320 patients were predominantly female (76%), mean age 61yrs (±13), 96.8% non-smokers, with chronic cough for 36 (18-117) months. Of 72 patients with heartburn, 20 (28%) noted improvement in their cough with acid suppression, whereas of 248 without heartburn, only 35 (14%) responded. Patients reporting heartburn were 2.7 (95% C.I. 1.3-5.6) times more likely to respond to acid suppression therapy (p=0.007).Conclusion: In specialist cough clinics, few patients report a response of their chronic cough to acid suppression therapy. Nonetheless, heartburn is a useful predictor substantially increasing the likelihood of benefit.
Use of adipose-derived stem cells in lymphatic tissue engineering and regeneration
Forte, Antonio J. , Boczar, Daniel , Sarabia-Estrada, Rachel , Huayllani, María T. , Ávila, Francisco R. , Guliyeva, Günel , Aung, Thiha , Quiñones‐Hinojosa, Alfredo , Torres, Ricardo A, Forte, Antonio Jorge , Sarabia-Estrada, Rachel , Avila, Francisco R , Torres‐Guzman, Ricardo A.

Mayo Clinic

Archives of Plastic Surgery | September 15, 2021 | Volume: 48 | Issue: 05 | Pages: 559-567

10.5999/aps.2021.00339 | PMID 34583446 Get It

The potential to differentiate into different cell lines, added to the easy and cost-effective method of extraction, makes adipose-derived stem cells (ADSCs) an object of interest in lymphedema treatment. Our study’s goal was to conduct a comprehensive systematic review of the use of ADSCs in lymphatic tissue engineering and regeneration. On July 23, 2019, using PubMed/MEDLINE, Cochrane Clinical Answers, Cochrane Central Register of Controlled Trials, and Embase databases, we conducted a systematic review of published literature on the use of ADSCs in lymphatic tissue engineering and regeneration. There were no language or time frame limitations, and the following search strategy was applied: ((Adipose stem cell) OR Adipose-derived stem cell)) AND ((Lymphedema) OR Breast Cancer Lymphedema). Only original research manuscripts were included. Fourteen studies fulfilled the inclusion criteria. Eleven studies were experimental (in vitro or in vivo in animals), and only three were clinical. Publications on the topic demonstrated that ADSCs promote lymphangiogenesis, and its effect could be enhanced by modulation of vascular endothelial growth factor-C, interleukin-7, prospero homeobox protein 1, and transforming growth factor-β1. Pilot clinical studies included 11 patients with breast cancer-related lymphedema, and no significant side effects were present at 12-month follow-up. Literature on the use of ADSCs in lymphatic tissue engineering and regeneration demonstrated promising data. Clinical evidence is still in its infancy, but the scientific community agrees that ADSCs can be useful in regenerative lymphangiogenesis. Data collected in this review indicate that unprecedented advances in lymphedema treatment can be anticipated in the upcoming years.
Single-fraction Stereotactic Radiosurgery for Atypical Meningiomas (WHO grade II): Treatment Results Based on a 25-year Experience
Hasegawa, Hirotaka , Vakharia, Kunal , Michael, Link J., Stafford, Scott L., Brown, Paul D. , Yan, Elizabeth , Mahajan, Anita , Laack, Nadia N., Pollock, Bruce E. , Parney, Ian F. , Burns, Terry C.

Mayo Clinic

No container title available | September 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-880804/v1 Get It

Abstract PurposeTo clarify the role of stereotactic radiosurgery (SRS) for atypical meningiomas (AM).MethodsA retrospective analysis of 68 patients with AM having SRS from 1995 until 2019. Nineteen patients (28%) had undergone prior external beam radiation therapy (EBRT) (median dose, 54 Gy). The median follow-up period was 52 months.ResultsEighteen (26%), 17 (25%), and 33 (49%) patients received SRS as an upfront adjuvant (≤ 6 months), early salvage (7-18 months), or late salvage treatment (> 18 months), respectively. The 3-, 5-, and 10-year progression-free survivals (PFSs) were 52%, 35%, and 25%, respectively. The 3-, 5-, and 10-year disease-specific survivals (DSSs) were 85%, 78%, and 61%, respectively. Adverse radiation events (AREs) were observed in 12 patients (18%), with increased or new seizures being the most frequent complication (n=7). Prior EBRT was associated with reduced PFS (HR = 5.92, P <0.01), reduced DSS (HR = 5.84, P <0.01), and an increased risk of ARE (HR = 3.31, P = 0.04). Timing of SRS was correlated with reduced PFS for patients having early salvage treatment compared to upfront adjuvant (HR = 3.17, P = 0.01) or late salvage treatment (HR = 4.39, P <0.01). ConclusionPFS for patients with residual/recurrent AM remains poor despite SRS. Prior EBRT was associated with worse tumor control, higher tumor-related mortality, and an increased risk of ARE. Further study on the timing of SRS is needed to determine if upfront adjunctive SRS improves tumor control compared to salvage SRS.
CORR Insights®: No Difference in Functional, Radiographic, and Survivorship Outcomes Between Direct Anterior or Posterior Approach THA: 5-Year Results of a Randomized Trial
Spangehl, Mark J. , Spangehl, Mark

Mayo Clinic

Clinical Orthopaedics & Related Research | September 15, 2021 | Volume: 479 | Issue: 12 | Pages: 2630-2632

10.1097/corr.0000000000001973 | PMID 34524981 Get It

Survival and associated comorbidities in inclusion body myositis
Naddaf, Elie , Shelly, Shahar , Mandrekar, Jay , Hoffman, E. Matthew , Ernste, Floranne C. , Liewluck, Teerin , Liewluck, T , Naddaf, Elie , Shahar, Shelly , Chamberlain, Alanna M.

Mayo Clinic

Rheumatology | September 15, 2021 | Volume: 61 | Issue: 5 | Pages: 2016-2024

10.1093/rheumatology/keab716 | PMID 34534271 Get It

Abstract Objective To evaluate survival and associated comorbidities in inclusion body myositis (IBM) in a population-based, case-control study. Methods We utilized the expanded Rochester Epidemiology Project medical records-linkage system, including 27 counties in Minnesota and Wisconsin, to identify patients with IBM, other inflammatory myopathies (IIM), and age/sex-matched population-controls. We compared the frequency of various comorbidities and survival among groups. Results We identified 50 IBM patients, 65 IIM controls and 294 population controls. Dysphagia was most common in IBM (64%) patients. The frequency of neurodegenerative disorders (dementia/parkinsonism) and solid cancers was not different between groups. Rheumatoid arthritis was the most common rheumatic disease in all groups. A total of 36% of IBM patients had a peripheral neuropathy, 6% had Sjögren’s syndrome and 10% had a haematologic malignancy. T-cell large granular lymphocytic leukaemia was only observed in the IBM group. None of the IBM patients had hepatitis B or C, or HIV. IBM patients were 2.7 times more likely to have peripheral neuropathy, 6.2 times more likely to have Sjögren’s syndrome and 3.9 times more likely to have a haematologic malignancy than population controls. IBM was associated with increased mortality, with a 10-year survival of 36% from index, compared with 67% in IIM and 59% in population controls. Respiratory failure or pneumonia (44%) was the most common cause of death. Conclusions IBM is associated with lower survival, and higher frequency of peripheral neuropathy, Sjögren’s syndrome and haematologic malignancies than the general population. Close monitoring of IBM-related complications is warranted.
Wolframin-1–expressing neurons in the entorhinal cortex propagate tau to CA1 neurons and impair hippocampal memory in mice
Delpech, Jean-Christophe , Pathak, Dhruba , Varghese, Merina , Kalavai, Srinidhi Venkatesan , Hays, Emma C. , Hof, Patrick R. , Johnson, W. Evan , Ikezu, Seiko , Luebke, Jennifer I. , Ikezu, Tsuneya , Medalla, Maria , Luebke, Jennifer I , Ikezu, Tsuneya , Medalla, Maria

Mayo Clinic

Science Translational Medicine | September 15, 2021 | Volume: 13 | Issue: 611 | Pages: No page available

10.1126/scitranslmed.abe8455 | PMID 34524859 Get It

Wolframin-1–positive neurons in the entorhinal cortex of mouse brain propagate tau to the hippocampal CA1 region resulting in memory impairment.
Very-Early-Onset Inflammatory Bowel Disease in a Patient With Junctional Epidermolysis Bullosa With a Homozygous Mutation in the α6 Integrin Gene (ITGA6)
Vahidnezhad, Hassan , Youssefian, Leila , Anbardar, Mohammad Hossein , Farahani, Rahele A., Uitto, Jouni , Uitto, Jouni , Zeinali, Sirous

Mayo Clinic

Inflammatory Bowel Diseases | September 15, 2021 | Volume: 27 | Issue: 11 | Pages: 1865-1869

10.1093/ibd/izab141 | PMID 34525201 Get It

Evaluation of the BinaxNOW COVID-19 Rapid Antigen Test in an Asymptomatic Patient Population Undergoing Preprocedural Screening
Stokes, Nadarra L., Reed, Katelyn A. , Berbari, Elie F. , Vetter, Sara M., Binnicker, Matthew J. , Stokes, Nadarra

Mayo Clinic

Journal of Clinical Microbiology | September 15, 2021 | Volume: 59 | Issue: 12 | Pages: No page available

10.1128/jcm.01650-21 | PMID 34524887 Get It

Outcomes of Primary Total Knee Arthroplasty Following Septic Arthritis of the Native Knee
Bettencourt, Jacob W. , Wyles, Cody C. , Fruth, Kristin M. , Osmon, Douglas R. , Hanssen, Arlen D. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Osmon, Douglas R , Wyles, Cody C , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | September 15, 2021 | Volume: 103 | Issue: 18 | Pages: 1685-1693

10.2106/jbjs.20.01678 | PMID 34524216 Get It

Background: Septic arthritis of the native knee often results in irreversible joint damage leading to the need for total knee arthroplasty (TKA). The purpose of the present study was to examine the intermediate-term risk of periprosthetic joint infection (PJI), aseptic revision, and reoperation following primary TKA in patients with a history of septic arthritis of the native knee as compared with primary TKA performed for the treatment of osteoarthritis. Methods: We retrospectively identified 215 primary TKAs performed from 1971 to 2016 at a single institution in patients with a history of septic arthritis of the native knee. Each case was matched 1:1 based on age, sex, body mass index (BMI), and surgical year to a TKA for osteoarthritis. The mean age and BMI were 63 years and 30 kg/m 2 , respectively. The mean duration of follow-up was 9 years. Results: Survivorships free of PJI at 10 years were 90% and 99% for the septic arthritis and osteoarthritis groups, respectively (hazard ratio [HR] = 6.1; p < 0.01). Ten-year survivorships free of any aseptic revisions were 83% and 93% (HR = 2.5; p < 0.01), and survivorships free of any reoperation were 61% and 84% (HR = 2.9; p < 0.01) for the septic arthritis and osteoarthritis groups, respectively. In addition, as time from the diagnosis of native knee septic arthritis to TKA increased, the relative risk of subsequent infection decreased. Preoperative and 2-year postoperative Knee Society scores were similar between the groups (p = 0.16 and p = 0.19, respectively). Conclusions: There was a 6.1-fold increased risk of PJI in patients undergoing TKA with a history of native knee septic arthritis when compared with controls undergoing TKA for the treatment of osteoarthritis, with a cumulative incidence of 9% at 10 years. Subgroup analysis of the septic arthritis cohort revealed a higher risk of any infection in patients who underwent TKA within the first 5 to 7 years after the diagnosis of septic arthritis as compared with those with a greater duration. Moreover, the 10-year rates of survival free of aseptic revision, any revision, and any reoperation were significantly worse in the native knee septic arthritis cohort. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.